Therefore, since heterozygous TACI mutations occur in healthy controls and clinical presentation ranges from unaffected to severe immunodeficiency, these TACI mutations are not validated in having direct functional consequences. This evidence concerns the gene TNFRSF13B and Immunodeficiency.